Immunomedics, Inc. (IMMU) Reports Progress With Labeling Proteins, Including Antibodies, for Improved PET Imaging
6/13/2013 8:57:54 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
VANCOUVER, British Columbia, June 12, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today reported progress with labeling temperature-sensitive molecules using fluorine-18 (18F) for improved positron-emission tomography (PET) imaging of diseases. Results of this study were presented by William McBride, Ph.D., Senior Director, Peptide Chemistry.
Help employers find you! Check out all the jobs and post your resume.
comments powered by